The Pipeline grants from CurePSP support projects translational projects focusing on new therapeutics and biomarkers for progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Applications are open to researchers around the world, except for those from countries where there is a trade sanction or embargo by the US government.
Key areas of interest include:
- Validation of novel drug targets
- Cell replacement therapy/regenerative approaches
- Biomarker validation (diagnostic, disease progression, comorbidities)
- Prodromal and early-stage diagnostic markers
- Diagnostic platform validation (e.g., RT-QuIC)
- Proof-of-concept clinical trials
- Rehabilitation strategies for motor and nonmotor deficits
- RNA-based neuroprotection
- Symptomatic clinical drug trials
- Symptomatic clinical non-pharmacological trials
The Grant provides 100,000 USD for up to 2 years.
Applications close on October 15, 2025.